X4 Pharmaceuticals, Inc. (XFOR)
| Market Cap | 228.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -101.17M |
| Shares Out | 167.94M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,413,021 |
| Open | 1.290 |
| Previous Close | 1.260 |
| Day's Range | 1.200 - 1.360 |
| 52-Week Range | 0.572 - 2.575 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+120.59%) |
| Earnings Date | May 2, 2024 |
About XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutrop... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 120.59% from the latest price.
News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective o...
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management w...
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it wil...
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on...
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management wi...
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
U.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if a...
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will...
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024 If the NDA is approved, company eligible to receive a Priority Review Voucher (PRV) resulting from mavorixafor's ...
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of...
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management w...
X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management w...
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
Submission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial Submission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
Submission of first U.S. New Drug Application for mavorixafor in WHIM syndrome on track for early 2H 2023 Emerging data from ongoing Phase 2 trial in certain chronic neutropenic disorders show mavori...
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of t...
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the ...
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of ...
X4 Pharmaceuticals Expected to Join Russell 3000® Index
BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the ...
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p75% reduction in the percentage of individuals experiencing severe infections (Grade 3 or higher) in the mavorixaf...
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit people with rare diseases of...
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
Company to host webinar event on May 16 th presenting new clinical data from the 4WHIM Phase 3 trial; oral presentation to follow on May 21 st at the 2023 Clinical Immunology Society (CIS) Annual Meet...
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of ...
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader ...
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early